[Clinical experience with gentamicin in urinary tract infections (author's transl)].

1) Gentamicin (GM) was intramuscularly injected to 1 patient with simple acute cystitis and to 21 patients with complicated chronic urinary tract infections in the doses of 40-160 mg per day for 3-12 days (mean: 5-2 days). 2) The clinical effect was excellent in 6, good in 9, poor in 7, which is classified as excellent in 1 with simple acute cystitis, good in 5 and poor in 5 out of 11 with complicated chronic cystitis, and excellent in 4, good in 4 and poor in 2 out of 10 with complicated chronic pyelonephritis. 3) In complicated urinary tract infections, the effective rate was 61.5% (8/13) in GM 80 mg/day dosage group and 75.0% (6/8) in GM 120 mg/day dosage group. 4) No abnormal change was noted in the kidney, liver and auditory function throughout this clinical study. 5) When GM therapy is conducted in the treatment of complicated urinary tract infections, it is considered that more favorable clinical results could be obtained with dosage of GM 120 mg/day or more. However, in this case a caution has to be paid to the kidney and auditory functions.

[Clinical study of UFT chemotherapy in renal cancer. Kyushu University Cooperative Study Group of Renal Cancer].

Clinical effects of UFT chemotherapy for renal cancer were evaluated by 19 collaborating hospitals. UFT (300-600 mg/day) was administered for more than 3 months. Of the 30 patients entered in this study, 21 were evaluable for the antitumor effects of the drug. Of the 21 evaluable patients, complete response (CR) was obtained in 2 patients, partial response (PR) in 1, no change (NC) in 7, progressive disease (PD) in 11, respectively. The response rate was 0% in patients with primary lesion and 21.4% in nephrectomized patients with metastatic lesion. Responses were observed in the metastases of lung, pleura and mediastinal lymph node. The main side effects in 27 patients were gastrointestinal symptoms. No significant abnormality was noted on blood laboratory data. In one patient the drug was discontinued within 3 months because of gastrointestinal symptoms. These results suggested that UFT chemotherapy for advanced renal cancer was clinically effective.

Effects of presensitization of antiheart serum on the rat embryonic heart.

After sensitization by rabbit anti-rat-heart serum (AHS), Wistar rats were injected with 9 ml/kg of AHS on day 9 of gestation. The incidence of malformations was 31.5% and that of cardiovascular malformations was 21.8%. The main malformations were microphthalmia, ventricular septal defect, pulmonary stenosis, and general edema. No antinuclear antibody was detected in the maternal sera by the fluorescent antibody technique. No complete heart block was found in the fetuses by electrocardiography. The fluorescent antibody technique demonstrated localization of rat IgG and rat C3 on the maternal myocardium, but a light-microscopic study revealed no myocarditis or endocarditis in either the maternal or the fetal heart. The types of malformation were similar to those observed after a single administration of antikidney serum, which presumably involves yolk sac dysfunction. These results show that both the existence of the immune complexes of antibodies against AHS and the administration of AHS on day 9 are necessary to cause yolk sac dysfunction or other teratogenic changes.

Synergistic effect of subteratogenic doses of antisera on the development in the rat.

Wistar rats were administered rabbit anti-rat-umbilical-cord serum (AUCS) alone on day 9 of gestation or in combination with subteratogenic doses of rabbit anti-rat-kidney serum (AKS). The results showed that the incidence of malformation was low (13.1% +/- 7.0 S.E.) even when very high doses of AUCS alone were administered. However, the incidence markedly increased to 61.0% +/- 9.3 S.E. when a small dose (0.10 ml/100 gm) of AKS was administered on day 9 followed by 0.90 ml/100 gm of AUCS on day 10. The malformations included microphthalmia, hydrocephaly, aortic arch anomalies, ventricular septal defect, and anophthalmia, being similar to the effects of a medium dose of AKS. These results suggest that a combination of subteratogenic doses of teratogenic antisera produces malformations, possibly by mechanisms that potentiate the teratogenic action of the sera.

The effects of M-protein fraction of hemolytic streptococci on embryonic heart in the rat.

Wistar rats were administered M-protein fraction (MP) of group A type 12 hemolytic streptococci on day 9 of gestation. When 9 mg/kg of MP was injected, the incidence of malformations was 11.8%, and the incidence of cardiovascular malformations was 7.9%. The main malformations were ventricular septal defect, microphthalmia, and hydrocephaly. Light and electron microscopic studies revealed no myocarditis nor endocarditis in either the maternal or fetal heart. Fluorescent antibody technique demonstrated no immunological cross-reaction between MP and rat heart tissue. The results suggest that MP is slightly teratogenic in the rat.